4.7 Article

Dutch National Round Robin Trial on Plasma-Derived Circulating Cell-Free DNA Extraction Methods Routinely Used in Clinical Pathology for Molecular Tumor Profiling

Journal

CLINICAL CHEMISTRY
Volume 68, Issue 7, Pages 963-972

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/clinchem/hvac069

Keywords

cancer; clinical investigation; molecular diagnostics; nucleic acid-based testing; quantitative analysis of nucleic acids; tumor markers

Funding

  1. ZonMw 'Personalised Medicine' programme [848101011]
  2. AstraZeneca
  3. Roche Diagnostics
  4. Abbott
  5. Agena Bioscience
  6. Bayer
  7. Biocartis
  8. Bio-Rad
  9. Boehringer Ingelheim
  10. CC Diagnostics
  11. Invitae/Archer
  12. Roche

Ask authors/readers for more resources

This study evaluated the impact of different ccfDNA extraction methods on yield, quality, and mutant ctDNA detection. Results showed that silica membrane-based methods had the highest ccfDNA yield and were preferred for detecting low copy numbers of relevant mutations. Harmonization of the extraction workflow is necessary to prevent technical divergence and interlaboratory discrepancies.
Background Efficient recovery of circulating tumor DNA (ctDNA) depends on the quantity and quality of circulating cell-free DNA (ccfDNA). Here, we evaluated whether various ccfDNA extraction methods routinely applied in Dutch laboratories affect ccfDNA yield, ccfDNA integrity, and mutant ctDNA detection, using identical lung cancer patient-derived plasma samples. Methods Aliquots of 4 high-volume diagnostic leukapheresis plasma samples and one artificial reference plasma sample with predetermined tumor-derived mutations were distributed among 14 Dutch laboratories. Extractions of ccfDNA were performed according to local routine standard operating procedures and were analyzed at a central reference laboratory for mutant detection and assessment of ccfDNA quantity and integrity. Results Mutant molecule levels in extracted ccfDNA samples varied considerably between laboratories, but there was no indication of consistent above or below average performance. Compared to silica membrane-based methods, samples extracted with magnetic beads-based kits revealed an overall lower total ccfDNA yield (-29%; P < 0.0001) and recovered fewer mutant molecules (-41%; P < 0.01). The variant allelic frequency and sample integrity were similar. In samples with a higher-than-average total ccfDNA yield, an augmented recovery of mutant molecules was observed. Conclusions In the Netherlands, we encountered diversity in preanalytical workflows with potential consequences on mutant ctDNA detection in clinical practice. Silica membrane-based methodologies resulted in the highest total ccfDNA yield and are therefore preferred to detect low copy numbers of relevant mutations. Harmonization of the extraction workflow for accurate quantification and sensitive detection is required to prevent introduction of technical divergence in the preanalytical phase and reduce interlaboratory discrepancies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available